

Nicotinic and muscarinic subtypes in the human brain.

Journal of Neuroscience Research

31, 103-111

DOI: [10.1002/jnr.490310115](https://doi.org/10.1002/jnr.490310115)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Neonatal nicotine exposure induces permanent changes in brain nicotinic receptors and behaviour in adult mice. <i>Developmental Brain Research</i> , 1991, 63, 201-207.	2.1	79
2	Biological markers and the cholinergic hypothesis in Alzheimer's disease. <i>Acta Neurologica Scandinavica</i> , 1992, 85, 54-58.	1.0	47
3	Effects of nucleus basalis lesion on muscarinic receptor subtypes. <i>Experimental Brain Research</i> , 1993, 97, 225-32.	0.7	15
4	Decline in Response to Nicotine in Aged Rat Striatum: Correlation with a Decrease in a Subpopulation of Nicotinic Receptors. <i>Journal of Neurochemistry</i> , 1993, 61, 2225-2232.	2.1	22
5	Differential effects of scopolamine and mecamylamine on working and reference memory in the rat. <i>Pharmacology Biochemistry and Behavior</i> , 1993, 45, 533-538.	1.3	64
6	The competition of (?)-[3H]nicotine binding by the enantiomers of nicotine, nornicotine and anatoxin-a in membranes and solubilized preparations of different brain regions of rat. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 1993, 348, 28-34.	1.4	43
7	Muscarinic and nicotinic receptor changes in the cortex and thalamus of brains of chronic alcoholics. <i>Brain Research</i> , 1993, 620, 42-48.	1.1	24
8	Clinical studies in Alzheimer patients with positron emission tomography. <i>Behavioural Brain Research</i> , 1993, 57, 215-224.	1.2	67
9	Age-related changes in human muscarinic acetylcholine receptors measured by positron emission tomography. <i>Neuroscience Letters</i> , 1993, 149, 225-228.	1.0	63
10	In Vivo Detection of Neurotransmitter Changes in Alzheimer's Disease. <i>Annals of the New York Academy of Sciences</i> , 1993, 695, 27-33.	1.8	30
11	Chapter 6: CNS distribution of cholinergic receptors - some questions from a clinical neuroscientist. <i>Progress in Brain Research</i> , 1993, 98, 73-75.	0.9	1
12	In vivo metabolic studies of the trans-(R,R) isomer of radioiodinated IQNP: A new ligand with high affinity for the M1 muscarinic-cholinergic receptor. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1994, 21, 1293-1297.	2.2	6
13	Synthesis and biological evaluation of iodine-125 iodocaramiphen. A potential M1 muscarinic imaging agent for SPECT. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1994, 34, 239-246.	0.5	3
14	Area specific alterations in muscarinic stimulated low Km GTPase activity in aging and Alzheimer's disease: implications for altered signal transduction. <i>Brain Research</i> , 1994, 664, 54-60.	1.1	33
15	Neurotransmitter receptor plasticity in aging. <i>Life Sciences</i> , 1994, 55, 1985-1991.	2.0	25
16	Cancer versus Alzheimer risks. Health is not mortal. <i>Biomedicine and Pharmacotherapy</i> , 1994, 48, 273.	2.5	0
17	Human nicotinic receptors—Their role in aging and dementia. <i>Neurochemistry International</i> , 1994, 25, 93-97.	1.9	109
18	Chapter 9 The central cholinergic system during aging. <i>Progress in Brain Research</i> , 1994, 100, 67-71.	0.9	62

#	ARTICLE	IF	CITATIONS
19	Genetic and environmental aspects of the role of nicotinic receptors in neurodegenerative disorders: Emphasis on Alzheimer's disease and Parkinson's disease. <i>Behavior Genetics</i> , 1995, 25, 149-159.	1.4	88
20	Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety. <i>Pharmacology Biochemistry and Behavior</i> , 1995, 51, 509-514.	1.3	188
21	Diminution of preprosomatostatin-mRNA in cerebral cortex of the aged rat. <i>Neurochemistry International</i> , 1995, 27, 481-487.	1.9	1
22	The Pharmacotherapy of Alzheimer's Disease Based on the Cholinergic Hypothesis: an Update. <i>Experimental Neurology</i> , 1995, 4, 349-356.	1.7	96
23	Long-term effects of bifemelane hydrochloride on post-stroke deterioration of cognitive function and cerebral blood flow. <i>Current Therapeutic Research</i> , 1995, 56, 231-238.	0.5	0
24	Muscarinic M1-Receptor Agonists. <i>CNS Drugs</i> , 1995, 3, 467-481.	2.7	14
25	Cholinergic markers in aged cognitively impaired long-evans rats. <i>Neuroscience</i> , 1995, 67, 277-292.	1.1	75
26	Potassium, but not atropine-stimulated cortical acetylcholine efflux, is reduced in aged rats. <i>Neurobiology of Aging</i> , 1996, 17, 565-571.	1.5	37
27	Evaluation of 1-azabicyclo[2.2.2]oct-3-yl $\hat{1}\pm$ -fluoroalkyl- $\hat{1}\pm$ -hydroxy- $\hat{1}\pm$ -phenylacetates as potential ligands for the study of muscarinic receptor density by positron emission tomography. <i>Nuclear Medicine and Biology</i> , 1996, 23, 267-276.	0.3	4
28	Acute and chronic nicotine effects on working memory in aged rats. <i>Psychopharmacology</i> , 1996, 123, 88-97.	1.5	146
29	Application of PET in dementia disorders. <i>Acta Neurologica Scandinavica</i> , 1996, 94, 71-76.	1.0	34
30	Aging, Smoking and EEG Coherence: A Preliminary Study. <i>Clinical EEG (electroencephalography)</i> , 1997, 28, 236-244.	0.9	18
31	Aging, Smoking and Hemispheric EEG Asymmetry. <i>Canadian Journal on Aging</i> , 1997, 16, 647-664.	0.6	7
32	Chapter 9 Changes in Neurotransmitter Signal Transduction Pathways in the Aging Brain. <i>Advances in Cell Aging and Gerontology</i> , 1997, , 243-278.	0.1	6
33	Expression of $\hat{1}\pm$ 4-1 and $\hat{1}\pm$ 5 Nicotinic Cholinoceptor mRNA in the Aging Rat Cerebral Cortex. <i>Neurobiology of Aging</i> , 1997, 18, 335-342.	1.5	14
34	Cholinergic activity and amyloid precursor protein metabolism. <i>Brain Research Reviews</i> , 1997, 25, 50-69.	9.1	118
35	Human neuronal nicotinic receptors. <i>Progress in Neurobiology</i> , 1997, 53, 199-237.	2.8	391
36	Effect of stimulation of nicotinic cholinergic receptors on cortical cerebral blood flow and changes in the effect during aging in anesthetized rats. <i>Neuroscience Letters</i> , 1997, 228, 203-206.	1.0	70

#	ARTICLE	IF	CITATIONS
37	Nicotinic receptors, muscarinic receptors and choline acetyltransferase activity in the temporal cortex of Alzheimer patients with differing apolipoprotein E genotypes. <i>Neuroscience Letters</i> , 1997, 232, 37-40.	1.0	40
38	Is Binding to Nicotinic Acetylcholine and Dopamine Receptors Related to Working Memory in Rats?. <i>Brain Research Bulletin</i> , 1997, 43, 295-304.	1.4	29
39	Heme from Alzheimer's brain inhibits muscarinic receptor binding via thiyl radical generation1An abstract of some of these findings was published in <i>Mol. Biol. Cell</i> , 7:S (1996) #3765.1. <i>Brain Research</i> , 1997, 764, 93-100.	1.1	33
40	Functional and neurobiological similarities of aging in monkeys and humans. <i>Age</i> , 1997, 20, 29-44.	3.0	16
41	Synthesis of 3-[(1-[11C]methyl-2(S)-pyrrolidinyl) methoxy]pyridine and 3-[(1-[11C]methyl-2(R)-pyrrolidinyl) methoxy]pyridine: Radioligands for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1997, 39, 425-431.	0.5	10
42	Autoradiographic distribution of M1, M2, M3, and M4 muscarinic receptor subtypes in Alzheimer's disease. , 1997, 26, 341-350.		98
43	[125/123I]IPH: A radioiodinated analog of epibatidine for in vivo studies of nicotinic acetylcholine receptors. , 1997, 26, 392-399.		52
44	Alterations with aging and ischemia in nicotinic acetylcholine receptor subunits $\hat{1}\pm 4$ and $\hat{1}^2$ messenger RNA expression in postmortem human putamen. Implications for susceptibility to parkinsonism. <i>Brain Research</i> , 1998, 791, 186-190.	1.1	40
45	Regional distribution of subtypes of nicotinic receptors in human brain and effect of aging studied by ($\hat{A}\pm$)-[. <i>Brain Research</i> , 1998, 801, 143-149.	1.1	92
46	Regional distribution of nicotinic receptors during prenatal development of human brain and spinal cord. <i>Developmental Brain Research</i> , 1998, 108, 147-160.	2.1	145
47	Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses. <i>Neuropsychopharmacology</i> , 1998, 19, 60-69.	2.8	57
48	Expression of nicotinic receptor \hat{a} and $\hat{1}^2$ subunits in the prenatal and aged human brain. <i>Journal of Physiology (Paris)</i> , 1998, 92, 438-439.	2.1	0
49	Resolution, in vitro and in vivo evaluation of fluorine-18-labeled isomers of 1-azabicyclo[2.2.2]oct-3-yl $\hat{1}\pm$ -(1-fluoropent-5-yl) $\hat{1}\pm$ -hydroxy- $\hat{1}\pm$ -phenylacetate (FQNPe) as new PET candidates for the imaging of muscarinic-cholinergic receptor. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 1998, 41, 681-704.	0.5	4
50	Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 1998, 105, 709-717.	1.4	36
51	Nicotinic acetylcholine involvement in cognitive function in animals. <i>Psychopharmacology</i> , 1998, 138, 217-230.	1.5	646
52	Age-related changes in rodent cortical acetylcholine and cognition: main effects of age versus age as an intervening variable. <i>Brain Research Reviews</i> , 1998, 27, 143-156.	9.1	68
53	Distribution of mRNA for the $\hat{1}\pm 4$ subunit of the nicotinic acetylcholine receptor in the human fetal brain. <i>Molecular Brain Research</i> , 1998, 58, 123-131.	2.5	43
54	Expression of the $\hat{1}\pm 3$ nicotinic receptor subunit mRNA in aging and Alzheimer's disease. <i>Molecular Brain Research</i> , 1998, 63, 72-78.	2.5	48

#	ARTICLE	IF	CITATIONS
55	Ageing Effects on the Startle Response and Startle Plasticity in Fischer F344 Rats. <i>Neurobiology of Aging</i> , 1998, 19, 243-251.	1.5	29
56	Age-related changes in nicotinic acetylcholine receptor subunits $\alpha 4$ and $\alpha 2$ messenger RNA expression in postmortem human frontal cortex and hippocampus. <i>Neuroscience Letters</i> , 1998, 245, 139-142.	1.0	53
57	Laminar distribution of nicotinic receptor subtypes in human cerebral cortex as determined by [^3H]-(-)-nicotine, [^3H]cytisine and [^3H]epibatidine in vitro autoradiography. <i>Neuroscience</i> , 1998, 85, 1121-1133.	1.1	54
58	Pharmacological evaluation of [^{11}C]A-84543: An enantioselective ligand for in vivo studies of neuronal nicotinic acetylcholine receptors. <i>Life Sciences</i> , 1998, 63, PL13-PL18.	2.0	28
59	In vivo imaging of brain nicotinic acetylcholine receptors with 5-[^{123}I]iodo-A-85380 using single photon emission computed tomography. <i>Life Sciences</i> , 1998, 63, PL355-PL360.	2.0	53
60	Smoking History and Aging-Associated Cognitive Decline: An Event-Related Brain Potential Study. <i>Neuropsychobiology</i> , 1999, 40, 95-106.	0.9	12
61	Neuropharmacology and Receptor Studies in the Elderly. <i>Journal of Geriatric Psychiatry and Neurology</i> , 1999, 12, 137-149.	1.2	9
62	Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. <i>European Journal of Neuroscience</i> , 1999, 11, 2551-2565.	1.2	144
63	Diminution of nicotinic receptor alpha 3 subunit mRNA expression in aged rat brain. <i>Developmental Brain Research</i> , 1999, 118, 153-158.	2.1	7
64	The cholinergic hypothesis of Alzheimer's disease: a review of progress. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 137-147.	0.9	1,714
65	Synthesis of an I-123 analog of A-85380 and preliminary SPECT imaging of nicotinic receptors in baboon. <i>Nuclear Medicine and Biology</i> , 1999, 26, 201-207.	0.3	62
66	A rapid and simple Sep Pak method for purification of radioiodinated IQNP, a high affinity ligand for the muscarinic receptor. <i>Nuclear Medicine and Biology</i> , 1999, 26, 859-863.	0.3	2
67	Age-related attenuation of stimulated cortical acetylcholine release in basal forebrain-lesioned rats. <i>Neuroscience</i> , 1999, 90, 793-802.	1.1	26
68	Autoradiographic comparison of [^3H](α^*)nicotine, [^3H]cytisine and [^3H]epibatidine binding in relation to vesicular acetylcholine transport sites in the temporal cortex in Alzheimer's disease. <i>Neuroscience</i> , 1999, 94, 685-696.	1.1	43
69	Age and species-dependent differences in the neurokinin B system in rat and human brain. <i>Neurobiology of Aging</i> , 1999, 20, 19-35.	1.5	24
70	Regional distribution of nicotinic receptor subunit mRNAs in human brain: comparison between Alzheimer and normal brain. <i>Molecular Brain Research</i> , 1999, 66, 94-103.	2.5	180
71	Nicotine improves memory in an object recognition task in rats. <i>European Neuropsychopharmacology</i> , 1999, 9, 323-327.	0.3	88
72	Reduced High-Affinity Agonist Binding at the M1 Muscarinic Receptor in Alzheimer's Disease Brain: Differential Sensitivity to Agonists and Divalent Cations. <i>Experimental Neurology</i> , 1999, 158, 451-458.	2.0	29

#	ARTICLE	IF	CITATIONS
73	Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2000, 11, 11-18.	0.7	85
75	Nicotinic receptors in dementia of Alzheimer, Lewy body and vascular types. <i>Acta Neurologica Scandinavica</i> , 2000, 102, 34-41.	1.0	52
76	Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases. <i>European Journal of Pharmacology</i> , 2000, 393, 215-222.	1.7	172
77	Neuronal nicotinic receptors, important new players in brain function. <i>European Journal of Pharmacology</i> , 2000, 393, 3-10.	1.7	101
78	Geriatric Psychopharmacology: Why Does Age Matter?. <i>Harvard Review of Psychiatry</i> , 2000, 7, 311-333.	0.9	25
79	Acute Nicotine Administration in Alzheimer's Disease: An Exploratory EEG Study. <i>Neuropsychobiology</i> , 2000, 41, 210-220.	0.9	20
80	Chronic treatment of old rats with donepezil or galantamine: effects on memory, hippocampal plasticity and nicotinic receptors. <i>Neuroscience</i> , 2000, 99, 17-23.	1.1	188
81	Nicotinic acetylcholine receptors during prenatal development and brain pathology in human aging. <i>Behavioural Brain Research</i> , 2000, 113, 159-168.	1.2	87
82	Drugs selective for nicotinic receptor subtypes: a real possibility or a dream?. <i>Behavioural Brain Research</i> , 2000, 113, 183-192.	1.2	52
83	Human post-mortem striatal $\alpha 4 \beta 2$ nicotinic acetylcholine receptor density in schizophrenia and Parkinson's syndrome. <i>Neuroscience Letters</i> , 2000, 287, 109-112.	1.0	104
84	Effects of age on cholinergic vasodilation of cortical cerebral blood vessels in rats. <i>Neuroscience Letters</i> , 2000, 294, 109-112.	1.0	45
85	Nicotinic receptor losses in dementia with Lewy bodies: comparisons with Alzheimer's disease. <i>Neurobiology of Aging</i> , 2000, 21, 741-746.	1.5	47
86	Synthesis and in vivo evaluation of (E)-N-[^{11}C]Methyl-4-(3-pyridinyl)-3-butene-1-amine ([^{11}C]metanicotine) as a nicotinic receptor radioligand. <i>Nuclear Medicine and Biology</i> , 2000, 27, 415-418.	0.3	7
87	Evaluation of Z-(R,R)-IQNP for the potential imaging of m2 mAChR rich regions of the brain and heart. <i>Life Sciences</i> , 2000, 66, 885-896.	2.0	8
88	Cholinergic Treatments of Alzheimer's Disease. , 2001, , 475-486.		4
89	Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. <i>Brain Research Reviews</i> , 2001, 35, 73-96.	9.1	284
90	Stereoselective synthesis, in vitro , and initial in vivo evaluation of 1-methylpiperidin-4-yl β -hydroxy- β -(1-iodo-1-propen-3-yl)- β -phenylacetate (IPIP): a novel radioiodinated molecular probe with high affinity for the muscarinic receptor. <i>Nuclear Medicine and Biology</i> , 2001, 28, 959-973.	0.3	0
91	[^{125}I / ^{123}I] 5-Iodo-3-pyridyl ethers. <i>Nuclear Medicine and Biology</i> , 2001, 28, 911-921.	0.3	15

#	ARTICLE	IF	CITATIONS
92	Expression of nicotinic acetylcholine receptors in human and rat adrenal medulla. <i>Life Sciences</i> , 2001, 70, 577-590.	2.0	34
93	Growth Hormone, Insulin-like Growth Factor- 1, and the Aging Brain. , 2001, , 907-928.		1
94	Targeting Cerebral Muscarinic Acetylcholine Receptors with Radioligands for Diagnostic Nuclear Medicine Studies. , 2001, , 17-38.		1
95	SPET imaging of central muscarinic acetylcholine receptors with iodine-123 labelled E-IQNP and Z-IQNP. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001, 28, 13-24.	2.2	12
96	Correlation of nicotinic receptor binding with clinical and neuropathological changes in Alzheimer's disease and dementia with Lewy bodies. <i>Journal of Neural Transmission</i> , 2001, 108, 1149-1157.	1.4	24
97	Does apolipoprotein E (Apo-E) genotype influence nicotinic receptor binding in Alzheimer's disease. <i>Journal of Neural Transmission</i> , 2001, 108, 1043-1050.	1.4	15
98	The developing cholinergic system as target for environmental toxicants, nicotine and polychlorinated biphenyls (PCBs): Implications for neurotoxicological processes in mice. <i>Neurotoxicity Research</i> , 2001, 3, 37-51.	1.3	49
99	Decreased Protein Levels of Nicotinic Receptor Subunits in the Hippocampus and Temporal Cortex of Patients with Alzheimer's Disease. <i>Journal of Neurochemistry</i> , 2001, 74, 237-243.	2.1	243
100	Assessment of muscarinic receptor concentrations in aging and Alzheimer disease with [11C]NMPB and PET. <i>Synapse</i> , 2001, 39, 275-287.	0.6	69
102	Cholinergic Activity in Autism: Abnormalities in the Cerebral Cortex and Basal Forebrain. <i>American Journal of Psychiatry</i> , 2001, 158, 1058-1066.	4.0	320
103	The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. <i>Journal of Alzheimer's Disease</i> , 2002, 4, 317-325.	1.2	52
104	The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease. <i>Journal of the Neurological Sciences</i> , 2002, 203-204, 131-136.	0.3	55
105	Cholinergic Nicotinic Systems in Alzheimer's Disease. <i>CNS Drugs</i> , 2002, 16, 485-500.	2.7	11
106	Muscarinic M1receptor agonists and M2receptor antagonists as therapeutic targets in Alzheimer's disease. <i>Expert Opinion on Therapeutic Patents</i> , 2002, 12, 863-870.	2.4	19
107	Regulation of cerebral cortical blood flow by the basal forebrain cholinergic fibers and aging. <i>Autonomic Neuroscience: Basic and Clinical</i> , 2002, 96, 13-19.	1.4	45
108	Alzheimer's disease and the basal forebrain cholinergic system: relations to β -amyloid peptides, cognition, and treatment strategies. <i>Progress in Neurobiology</i> , 2002, 68, 209-245.	2.8	595
109	Effects of Age, Postmortem Delay and Storage Time on Receptor-mediated Activation of G-proteins in Human Brain. <i>Neuropsychopharmacology</i> , 2002, 26, 468-478.	2.8	42
110	Role of amyloid β peptides in the regulation of central cholinergic function and its relevance to Alzheimer's disease pathology. <i>Drug Development Research</i> , 2002, 56, 248-263.	1.4	11

#	ARTICLE	IF	CITATIONS
111	Evaluation of radioiodinated S-iodo-3-(2(S)-anotidinymethoxy)pyridine as a ligand for SPECT investigations of brain nicotinic acetylcholine receptors. <i>Annals of Nuclear Medicine</i> , 2002, 16, 189-200.	1.2	39
112	Chronic treatments with tacrine and (α ⁷)-nicotine induce different changes of nicotinic and muscarinic acetylcholine receptors in the brain of aged rat. <i>Journal of Neural Transmission</i> , 2002, 109, 377-392.	1.4	25
113	The cholinergic pathology in Alzheimer's disease - discrepancies between clinical experience and pathophysiological findings. <i>Journal of Neural Transmission</i> , 2002, 109, 1003-1013.	1.4	80
114	Mechanism of nicotine-evoked release of [3 H]-noradrenaline in human cerebral cortex slices. <i>British Journal of Pharmacology</i> , 2002, 137, 1063-1070.	2.7	14
115	Quantification of nicotinic acetylcholine receptors in human brain using [123I]5-I-A-85380 SPET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003, 30, 1620-1629.	3.3	45
116	Synthesis of [18F]3-[1-(3-fluoropropyl)-(S)-pyrrolidin-2-ylmethoxy]pyridine ([18F]NicFP): a potential ² nicotinic acetylcholine receptor radioligand for PET. <i>Journal of Labelled Compounds and Radiopharmaceuticals</i> , 2003, 46, 1261-1268.	0.5	4
117	In vivo muscarinic 2 receptor imaging in cognitively normal young and older volunteers. <i>Synapse</i> , 2003, 48, 39-44.	0.6	64
118	DHA-enriched phospholipid diets modulate age-related alterations in rat hippocampus. <i>Neurobiology of Aging</i> , 2003, 24, 233-243.	1.5	95
119	Neurotransmitter Abnormalities in Vascular Dementia. <i>International Psychogeriatrics</i> , 2003, 15, 81-87.	0.6	19
120	Executive and social behaviors under nicotinic receptor regulation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 9596-9601.	3.3	157
121	Effects of donepezil treatment on rat nicotinic acetylcholine receptor levels in vivo and in vitro. <i>Journal of Alzheimer's Disease</i> , 2004, 5, 429-436.	1.2	17
122	Amyloid β ² peptides and central cholinergic neurons: functional interrelationship and relevance to Alzheimer's disease pathology. <i>Progress in Brain Research</i> , 2004, 145, 261-274.	0.9	31
123	Cholinergic modulation of microglial activation by α ⁷ nicotinic receptors. <i>Journal of Neurochemistry</i> , 2004, 89, 337-343.	2.1	498
124	Association of a salivary acetylcholinesterase with Alzheimer's disease and response to cholinesterase inhibitors. <i>Clinical Biochemistry</i> , 2004, 37, 98-104.	0.8	76
125	Decrease in GTP-sensitive high affinity agonist binding of muscarinic acetylcholine receptors in autopsied brains of dementia with Lewy bodies and Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 2004, 223, 145-148.	0.3	10
126	Neuronal nicotinic receptors: from structure to pathology. <i>Progress in Neurobiology</i> , 2004, 74, 363-396.	2.8	848
127	SPET imaging of central muscarinic receptors with (R,R)[123I]-I-QNB: methodological considerations. <i>Nuclear Medicine and Biology</i> , 2004, 31, 583-590.	0.3	24
128	Post-training intrahippocampal infusion of nicotine prevents spatial memory retention deficits induced by the cyclo-oxygenase-2-specific inhibitor celecoxib in rats. <i>Journal of Neurochemistry</i> , 2005, 95, 1078-1090.	2.1	54

#	ARTICLE	IF	CITATIONS
129	In vivo imaging of muscarinic receptors in the aging female brain with (,)[I]-QNB and single photon emission tomography. <i>Experimental Gerontology</i> , 2005, 40, 137-145.	1.2	29
130	Genes involved in Alzheimer's disease, a survey of possible candidates. <i>Journal of Alzheimer's Disease</i> , 2005, 7, 331-353.	1.2	30
131	Metabolic Patterns Associated With the Clinical Response to Galantamine Therapy. <i>Archives of Neurology</i> , 2005, 62, 721.	4.9	109
132	Acetylcholinergic neurotransmission and the β -amyloid cascade: implications for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2005, 5, 277-284.	1.4	24
133	Neurochemistry of severe dementia. <i>Reviews in Clinical Gerontology</i> , 2005, 15, 105-123.	0.5	1
134	Structural Determinants of α 2 Nicotinic Acetylcholine Receptor Trafficking. <i>Journal of Neuroscience</i> , 2005, 25, 6676-6686.	1.7	52
135	Chronic nicotine administration exacerbates tau pathology in a transgenic model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 3046-3051.	3.3	188
136	Effect of repeated nicotine exposure on high-affinity nicotinic acetylcholine receptor density in spontaneously hypertensive rats. <i>Neuroscience Letters</i> , 2005, 382, 158-163.	1.0	13
137	Neuro-modulation, aminergic neuro-disinhibition and neuro-degeneration.. <i>Medical Hypotheses</i> , 2005, 65, 1106-1119.	0.8	20
138	Aging and subcellular localization of m2 muscarinic autoreceptor in basalcortical neurons in vivo. <i>Neurobiology of Aging</i> , 2005, 26, 1061-1072.	1.5	11
139	Simplified quantification of nicotinic receptors with 2[18F]F-A-85380 PET. <i>Nuclear Medicine and Biology</i> , 2005, 32, 585-591.	0.3	41
140	M1 Receptors Play a Central Role in Modulating AD-like Pathology in Transgenic Mice. <i>Neuron</i> , 2006, 49, 671-682.	3.8	383
141	Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 175.	1.0	126
142	PET imaging of cortical 11C-nicotine binding correlates with the cognitive function of attention in Alzheimer's disease. <i>Psychopharmacology</i> , 2006, 188, 509-520.	1.5	128
143	Altered synaptic function in Alzheimer's disease. <i>European Journal of Pharmacology</i> , 2006, 545, 11-21.	1.7	95
144	Acetylcholine Receptors and Tau Phosphorylation. <i>Current Molecular Medicine</i> , 2006, 6, 423-428.	0.6	33
145	Pharmacology of Acetylcholinesterase Inhibitors and N-methyl-D-aspartate Receptors for Combination Therapy in the Treatment of Alzheimer's Disease. <i>Journal of Clinical Pharmacology</i> , 2006, 46, 8S-16S.	1.0	69
147	Retinoic acid and nerve growth factor induce differential regulation of nicotinic acetylcholine receptor subunit expression in SN56 cells. <i>Journal of Neuroscience Research</i> , 2007, 85, 504-514.	1.3	10

#	ARTICLE	IF	CITATIONS
148	Electronic structure calculations toward new potentially AChE inhibitors. <i>Chemical Physics Letters</i> , 2007, 446, 304-308.	1.2	14
149	Modeling behavioral and neuronal symptoms of Alzheimer's disease in mice: A role for intraneuronal amyloid. <i>Neuroscience and Biobehavioral Reviews</i> , 2007, 31, 125-147.	2.9	202
150	The role of the nicotinic acetylcholine receptors in sleep-related epilepsy. <i>Biochemical Pharmacology</i> , 2007, 74, 1308-1314.	2.0	99
151	Changes in brain ¹¹ C- α -nicotine binding sites in patients with mild Alzheimer's disease following rivastigmine treatment as assessed by PET. <i>Psychopharmacology</i> , 2007, 191, 1005-1014.	1.5	57
152	Imaging of Cholinergic and Monoaminergic Neurochemical Changes in Neurodegenerative Disorders. <i>Molecular Imaging and Biology</i> , 2007, 9, 243-257.	1.3	64
153	The Application of Positron-Emitting Molecular Imaging Tracers in Alzheimer's Disease. <i>Molecular Imaging and Biology</i> , 2007, 9, 204-216.	1.3	27
154	Acetylcholine receptors in dementia and mild cognitive impairment. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008, 35, 30-45.	3.3	111
155	Effects of cholinesterase inhibitors on rat nicotinic receptor levels in vivo and in vitro. <i>Journal of Neural Transmission</i> , 2008, 115, 1437-1444.	1.4	14
156	Synthesis and In-Vivo Evaluation of [¹¹ C]p-PVP-MEMA as a PET Radioligand for Imaging Nicotinic Receptors. <i>Australian Journal of Chemistry</i> , 2008, 61, 438.	0.5	5
157	Relationship between nicotinic receptors and cognitive function in early Alzheimer's disease: A 2-[¹⁸ F]fluoro-A-85380 PET study. <i>Neurobiology of Learning and Memory</i> , 2008, 90, 404-412.	1.0	56
158	Chronic nicotine and dizocilpine effects on nicotinic and NMDA glutamatergic receptor regulation: Interactions with clozapine actions and attentional performance in rats. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008, 32, 1030-1040.	2.5	19
159	Chapter 1 Cholinergic components of frontal lobe function and dysfunction. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 88, 1-30.	1.0	2
160	Neuronal Nicotinic Receptor Deficits in Alzheimer Patients with the Swedish Amyloid Precursor Protein 670/671 Mutation. <i>Journal of Neurochemistry</i> , 2008, 72, 1161-1169.	2.1	57
161	Pharmacology of the Intracellular Pathways Activated by Amyloid Beta Protein. <i>Mini-Reviews in Medicinal Chemistry</i> , 2009, 9, 724-740.	1.1	17
162	M1 Agonists as a Potential Disease-Modifying Therapy for Alzheimers Disease. <i>Current Alzheimer Research</i> , 2009, 6, 112-117.	0.7	56
163	¹²³ I-5-IA-85380 SPECT Imaging of Nicotinic Receptors in Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1455-1463.	2.8	36
164	Prenatal nicotine exposure alters medullary nicotinic and AMPA-mediated control of respiratory frequency in vitro. <i>Respiratory Physiology and Neurobiology</i> , 2009, 169, 1-10.	0.7	23
165	Long-term nicotine treatment reduces cerebral cortical vasodilation mediated by α 2-like nicotinic acetylcholine receptors in rats. <i>European Journal of Pharmacology</i> , 2009, 609, 100-104.	1.7	9

#	ARTICLE	IF	CITATIONS
166	Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. <i>Journal of Neurology</i> , 2009, 256, 717-720.	1.8	33
167	Galantamine-induced improvements in cognitive function are not related to alterations in $\alpha 7$ nicotinic receptors in early Alzheimer's disease as measured in vivo by 2-[18 F]Fluoro-A-85380 PET. <i>Psychopharmacology</i> , 2009, 202, 79-91.	1.5	20
168	The relationship between nicotinic receptors and cognitive functioning in healthy aging: An in vivo positron emission tomography (PET) study with [18 F]fluoro-A-85380. <i>Synapse</i> , 2009, 63, 752-763.	0.6	22
169	New potential AChE inhibitor candidates. <i>European Journal of Medicinal Chemistry</i> , 2009, 44, 3754-3759.	2.6	46
170	Age-related decline in nicotinic receptor availability with [123 I]5-IA-85380 SPECT. <i>Neurobiology of Aging</i> , 2009, 30, 1490-1497.	1.5	54
171	Basal forebrain stimulation induces NGF secretion in ipsilateral parietal cortex via nicotinic receptor activation in adult, but not aged rats. <i>Neuroscience Research</i> , 2009, 63, 122-128.	1.0	52
172	Central in Vivo Nicotinic Acetylcholine Receptor Imaging Agents for Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT). <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 337-340.	0.6	18
173	Cerebral Cortical Vasodilatation Mediated by Nicotinic Cholinergic Receptors: Effects of Old Age and of Chronic Nicotine Exposure. <i>Biological and Pharmaceutical Bulletin</i> , 2009, 32, 341-344.	0.6	21
174	Cholinergic Central System, Alzheimer's Disease, and Anesthetics Liaison: A Vicious Circle?. <i>Journal of Alzheimer's Disease</i> , 2010, 22, S35-S41.	1.2	17
175	Alzheimer's Disease Amyloid β -Protein and Synaptic Function. <i>NeuroMolecular Medicine</i> , 2010, 12, 13-26.	1.8	122
176	Aging of the autonomic nervous system and possible improvements in autonomic activity using somatic afferent stimulation. <i>Geriatrics and Gerontology International</i> , 2010, 10, S127-36.	0.7	118
177	Quantification of Smoking-Induced Occupancy of $\alpha 7$ -Nicotinic Acetylcholine Receptors: Estimation of Nondisplaceable Binding. <i>Journal of Nuclear Medicine</i> , 2010, 51, 1226-1233.	2.8	33
178	M1 muscarinic receptor for the development of auditory cortical function. <i>Molecular Brain</i> , 2010, 3, 29.	1.3	17
179	Intact cannabinoid CB1 receptors in the Alzheimer's disease cortex. <i>Neurochemistry International</i> , 2010, 57, 985-989.	1.9	59
180	Specific inhibitory effect of amyloid- β on presynaptic muscarinic receptor subtypes modulating neurotransmitter release in the rat nucleus accumbens. <i>Neuroscience</i> , 2010, 167, 482-489.	1.1	17
181	Beyond the Cholinergic Hypothesis: Do Current Drugs Work in Alzheimer's Disease?. <i>CNS Neuroscience and Therapeutics</i> , 2010, 16, 235-245.	1.9	122
182	Role of Vascular Risk Factors and Vascular Dysfunction in Alzheimer's Disease. <i>Mount Sinai Journal of Medicine</i> , 2010, 77, 82-102.	1.9	181
183	Cognitive Impairment in Acquired Brain Injury: A Predictor of Rehabilitation Outcomes and an Opportunity for Novel Interventions. <i>PM and R</i> , 2011, 3, S45-51.	0.9	40

#	ARTICLE	IF	CITATIONS
184	The history of the cholinergic hypothesis. Behavioural Brain Research, 2011, 221, 334-340.	1.2	319
185	Attenuation of neurodegenerative phenotypes in Alzheimer-like presenilin 1/presenilin 2 conditional double knockout mice by EUK1001, a promising derivative of xanomeline. Biochemical and Biophysical Research Communications, 2011, 410, 229-234.	1.0	25
186	Compensatory responses to age-related decline in odor quality acuity: Cholinergic neuromodulation and olfactory enrichment. Neurobiology of Aging, 2011, 32, 2254-2265.	1.5	26
187	Decreased $\alpha 4\beta 2$ nicotinic receptor number in the absence of mRNA changes suggests posttranscriptional regulation in the spontaneously hypertensive rat model of ADHD. Journal of Neurochemistry, 2011, 119, 240-250.	2.1	13
188	Decreased cerebral $\alpha 4\beta 2^*$ nicotinic acetylcholine receptor availability in patients with mild cognitive impairment and Alzheimer's disease assessed with positron emission tomography. European Journal of Nuclear Medicine and Molecular Imaging, 2011, 38, 515-525.	3.3	109
189	Stress and the $\alpha 7$ Nicotinic Acetylcholine Receptor. Current Drug Targets, 2012, 13, 607-612.	1.0	9
190	Targeting Synaptic Dysfunction in Alzheimer's Disease Therapy. Molecular Neurobiology, 2012, 46, 572-587.	1.9	80
191	The nicotinic acetylcholine receptor: smoking and alzheimer's disease revisited. Frontiers in Bioscience - Elite, 2012, E4, 169.	0.9	9
192	The missing link between long-term stimulation of nicotinic receptors and the increases of acetylcholine release and vasodilation in the cerebral cortex of aged rats. Journal of Physiological Sciences, 2013, 63, 95-101.	0.9	5
193	Thalamo-cortical mechanisms underlying changes in amplitude and frequency of human alpha oscillations. NeuroImage, 2013, 70, 150-163.	2.1	73
194	Nicotine effects on attentional reorienting in mid-age adults, and interactions with apolipoprotein E status. Journal of Psychopharmacology, 2013, 27, 1007-1014.	2.0	8
195	Human Brain Imaging of Acetylcholine Receptors. , 2014, , 113-160.		0
196	Cholinergic Vasodilative System in the Cerebral Cortex: Effects of Acupuncture and Aging. JAMS Journal of Acupuncture and Meridian Studies, 2014, 7, 173-179.	0.3	2
197	Nicotinic Receptors and Attention. Current Topics in Behavioral Neurosciences, 2015, 23, 103-135.	0.8	31
199	Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease. Neuropeptides, 2015, 52, 1-18.	0.9	405
200	Transmitter Receptor Distribution in the Human Brain. , 2015, , 261-275.		21
201	Wake-active neurons across aging and neurodegeneration: a potential role for sleep disturbances in promoting disease. SpringerPlus, 2015, 4, 25.	1.2	41
202	Episodic memory in normal aging and Alzheimer disease: Insights from imaging and behavioral studies. Ageing Research Reviews, 2015, 24, 232-262.	5.0	255

#	ARTICLE	IF	CITATIONS
203	Neurogenic control of parenchymal arterioles in the cerebral cortex. <i>Progress in Brain Research</i> , 2016, 225, 3-39.	0.9	28
204	RGS2 expression predicts amyloid- β^2 sensitivity, MCI and Alzheimer's disease: genome-wide transcriptomic profiling and bioinformatics data mining. <i>Translational Psychiatry</i> , 2016, 6, e909-e909.	2.4	23
205	Mechanisms of Nicotine-Induced Neuroprotection: Inhibition of NADPH Oxidase and Subsequent Proton Channel Activation by Stimulating $\alpha 7$ Nicotinic Acetylcholine Receptor in Activated Microglia. <i>Advances in Neuroimmune Biology</i> , 2016, 6, 107-115.	0.7	1
206	Inhibited Expression of $\alpha 4\beta 2$ Nicotinic Acetylcholine Receptor in Blood Leukocytes of Chinese Patients with Vascular Dementia and in Blood Leukocytes as Well as the Hippocampus of Brain from Ischemic Rats. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 1377-1387.	1.7	1
207	Practical Pharmacology for Alzheimer's Disease. , 2016, , .		2
208	Potential Animal Models of Alzheimer Disease and Their Importance in Investigating the Pathogenesis of Alzheimer Disease. , 2016, , 77-111.		0
209	Nicotine inhibits activation of microglial proton currents via interactions with $\alpha 7$ acetylcholine receptors. <i>Journal of Physiological Sciences</i> , 2017, 67, 235-245.	0.9	30
210	Association between butyrylcholinesterase and cerebrospinal fluid biomarkers in Alzheimer's disease patients. <i>Neuroscience Letters</i> , 2017, 641, 101-106.	1.0	14
211	Impact of ageing on postsynaptic neuronal nicotinic neurotransmission in auditory thalamus. <i>Journal of Physiology</i> , 2017, 595, 5375-5385.	1.3	22
212	Functional activation of $G_{i/q}$ coupled to 5-HT _{2A} receptor and M1 muscarinic acetylcholine receptor in postmortem human cortical membranes. <i>Journal of Neural Transmission</i> , 2017, 124, 1123-1133.	1.4	13
213	Xanomeline derivative EUK1001 attenuates Alzheimer's disease pathology in a triple transgenic mouse model. <i>Molecular Medicine Reports</i> , 2017, 16, 7835-7840.	1.1	5
214	Geriatric Anesthesia: Age-Dependent Changes in the Central and Peripheral Nervous Systems. , 2018, , 145-160.		0
215	Cyto- and receptor architectonic mapping of the human brain. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2018, 150, 355-387.	1.0	43
216	Non-conventional compounds with potential therapeutic effects against Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2019, 19, 375-395.	1.4	12
217	G_i/o -Protein Coupled Receptors in the Aging Brain. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 89.	1.7	60
218	Adolescent Vulnerability to Alcohol Use Disorder: Neurophysiological Mechanisms from Preclinical Studies. <i>Handbook of Experimental Pharmacology</i> , 2019, 258, 421-442.	0.9	3
219	Future Therapeutic Perspectives into the Alzheimer's Disease Targeting the Oxidative Stress Hypothesis. <i>Molecules</i> , 2019, 24, 4410.	1.7	67
221	The role of nicotinic cholinergic neurotransmission in delusional thinking. <i>NPJ Schizophrenia</i> , 2020, 6, 16.	2.0	31

#	ARTICLE	IF	CITATIONS
222	Mechanisms of GABAergic and cholinergic neurotransmission in auditory thalamus: Impact of aging. <i>Hearing Research</i> , 2021, 402, 108003.	0.9	17
223	(+)-[18F]Flubatine as a novel $\alpha 4\beta 2$ nicotinic acetylcholine receptor PET ligand—results of the first-in-human brain imaging application in patients with $\beta 2$ -amyloid PET-confirmed Alzheimer's disease and healthy controls. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 731-746.	3.3	10
224	Central Activation of Alpha7 Nicotinic Signaling Attenuates LPS-Induced Neuroinflammation and Sickness Behavior in Adult but Not in Aged Animals. <i>Molecules</i> , 2021, 26, 2107.	1.7	7
225	Therapeutic Potential of Multifunctional Derivatives of Cholinesterase Inhibitors. <i>Current Neuropharmacology</i> , 2021, 19, 1323-1344.	1.4	14
226	Basal forebrain cholinergic system in the dementias: Vulnerability, resilience, and resistance. <i>Journal of Neurochemistry</i> , 2021, 158, 1394-1411.	2.1	42
227	Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies. <i>Neurochemical Research</i> , 2021, 46, 2832-2851.	1.6	18
228	Homomeric and Heteromeric $\alpha 7$ Nicotinic Acetylcholine Receptors in Health and Some Central Nervous System Diseases. <i>Membranes</i> , 2021, 11, 664.	1.4	20
229	Noninvasive Exploration of Nicotinic Acetylcholine Receptors In Vivo. <i>Handbook of Experimental Pharmacology</i> , 2000, , 539-561.	0.9	2
230	Involvement of Neuronal Nicotinic Receptors in Disease. <i>Handbook of Experimental Pharmacology</i> , 2000, , 751-778.	0.9	2
231	Neuronal Nicotinic Acetylcholine Receptors in Development and Aging. <i>Handbook of Experimental Pharmacology</i> , 2000, , 213-246.	0.9	2
232	The neurochemistry of Alzheimer type, vascular type and mixed type dementias compared. <i>Journal of Neural Transmission Supplementum</i> , 1996, 47, 73-101.	0.5	30
233	The cholinergic deficit in Alzheimer's disease: impact on cognition, behaviour and function. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 3-12.	1.0	30
234	Geriatric psychopharmacology: why does age matter?. <i>Harvard Review of Psychiatry</i> , 2000, 7, 311-333.	0.9	12
235	Interactions between reproductive transitions during aging and addiction: promoting translational crosstalk between different fields of research. <i>Behavioural Pharmacology</i> , 2021, 32, 112-122.	0.8	2
236	Effects of Stimulating the Nucleus Basalis of Meynert on Blood Flow and Delayed Neuronal Death Following Transient Ischemia in the Rat Cerebral Cortex.. <i>The Japanese Journal of Physiology</i> , 2002, 52, 383-393.	0.9	38
237	Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease. <i>Current Neuropharmacology</i> , 2014, 12, 2-36.	1.4	163
238	Pharmacological models in Alzheimer's disease research. <i>Dialogues in Clinical Neuroscience</i> , 2000, 2, 247-255.	1.8	28
239	Halogenated Coumarin-Chalcones as Multifunctional Monoamine Oxidase-B and Butyrylcholinesterase Inhibitors. <i>ACS Omega</i> , 2021, 6, 28182-28193.	1.6	26

#	ARTICLE	IF	CITATIONS
240	Brain aging research at the close of the 20th century: from bench to bedside. Dialogues in Clinical Neuroscience, 2001, 3, 167-180.	1.8	4
241	Dysfunction of the brain cholinergic system during aging and after lesions of the nucleus basalis of Meynert. , 1994, 44, 189-194.		9
242	Treatment of Alzheimer's Disease. , 1996, , .		0
243	The Rationale for Development of Cholinergic Therapies in ad. Advances in Behavioral Biology, 1998, , 445-450.	0.2	0
244	Central Cholinergic Nervous System and Cholinergic Agents. Acta Medica (Hradec Kralove), 1998, 41, 99-108.	0.2	1
246	Neurotransmitter receptors in Alzheimer's disease. , 2020, , 441-456.		0
247	Revisiting Alzheimerâ€™s Disease. , 2020, , 137-155.		0
248	Amyloid Î²-Peptide and Central Cholinergic Neurons: Involvement in Normal Brain Function and Alzheimerâ€™s Disease Pathology. , 2007, , 159-178.		0
249	Interactions between beta-amyloid and central cholinergic neurons: implications for Alzheimer's disease. Journal of Psychiatry and Neuroscience, 2004, 29, 427-41.	1.4	242
251	Biological determinants impact the neurovascular toxicity of nicotine and tobacco smoke: A pharmacokinetic and pharmacodynamics perspective. NeuroToxicology, 2022, 89, 140-160.	1.4	15
254	Modulation of Muscarinic Signalling in the Central Nervous System by Steroid Hormones and Neurosteroids. International Journal of Molecular Sciences, 2023, 24, 507.	1.8	2